{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06514001",
            "orgStudyIdInfo": {
                "id": "AMDX-2011P-204"
            },
            "organization": {
                "fullName": "Amydis Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of AMDX-2011P in Participants With Alzheimer's Disease",
            "officialTitle": "A Phase 2, Open Label, Study of AMDX-2011P as a Retinal Tracer in Participants With Alzheimer's Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-study-of-amdx-in-participants-with-alzheimer-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-17",
            "studyFirstSubmitQcDate": "2024-07-17",
            "studyFirstPostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Amydis Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).",
            "detailedDescription": "This open-label, masked endpoint assessment study will evaluate the safety, tolerability, plasma pharmacokinetics (PK) and biological activity of an intravenous (IV) dose of AMDX-2011P in participants with AD. Assessments of retinal images will be conducted by central masked assessors.\n\nParticipants will be admitted to the study site where eye examination and retinal imaging will be conducted before administration of the study drug. AMDX-2011P will be administered through a single IV bolus injection followed by safety assessments, retinal imaging and PK blood collection."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Disease"
            ],
            "keywords": [
                "AD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 25,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AMDX-2011P 100 milligram",
                    "type": "EXPERIMENTAL",
                    "description": "AMDX2011P 100 milligram (4 milliliter) single bolus injection intravenous for diagnostic review",
                    "interventionNames": [
                        "Drug: AMDX-2011P"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AMDX-2011P",
                    "description": "AMDX-2011P single bolus injection intravenous for diagnostic review",
                    "armGroupLabels": [
                        "AMDX-2011P 100 milligram"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "AMDX-2011P Adverse Events Profile",
                    "description": "Incidence, nature and severity of adverse events/serious adverse events (AEs/SAEs)",
                    "timeFrame": "8 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Concentration of AMDX-2011P",
                    "description": "Plasma Pharmacokinetic (PK) Concentration (CMax) AMDX-2011P to AMDX-2011",
                    "timeFrame": "2 hours"
                },
                {
                    "measure": "Pharmacokinetic Analysis of AMDX-2011P",
                    "description": "Area under the plasma versus time curve (AUC)",
                    "timeFrame": "2 hours"
                },
                {
                    "measure": "Biological Activity",
                    "description": "Detection of amyloid deposits in the retina after intravenous AMDX-2011P administration",
                    "timeFrame": "8 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Confirmed diagnosis of Alzheimer's Disease (AD) with documented positive amyloid beta signal via positron emission tomography (PET) brain scan\n2. Must be willing to consent to genotyping for apolipoprotein E (APOE)\n3. Ability to fixate and undergo retinal imaging of both eyes\n\nExclusion Criteria:\n\n1. Presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol\n2. Diagnosis of glaucoma, or suspect of having glaucoma in either eye as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination, visual field, and/or optical coherence tomography (OCT) results\n3. Diagnosis of intermediate dry, wet/neovascular, or geographic atrophy forms of age-related macular degeneration (AMD) in either eye, OR as determined by an ophthalmologist as a clinical investigator, based on results from the eye examination and/or optical coherence tomography (OCT) results\n4. Clinically significant laboratory abnormalities as assessed by the investigator\n5. Prolonged QTcF (corrected QT interval by Fridericia method) (\\>450 ms for males and \\>470 ms for females), cardiac arrhythmia, or any clinically significant abnormality in the resting electrocardiogram (ECG), as judged by the investigator.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joyce Simpauco, MPH",
                    "role": "CONTACT",
                    "phone": "858-254-7435",
                    "email": "joyce@amydis.com"
                },
                {
                    "name": "David Bingaman, DVM, PhD",
                    "role": "CONTACT",
                    "email": "david.bingaman@amydis.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "David Bingaman, DVM, PhD",
                    "affiliation": "Amydis Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Associated Retina Consultants",
                    "status": "RECRUITING",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85020",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mallory Mintert",
                            "role": "CONTACT",
                            "email": "mallory.mintert@doctrials.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "Global Research Management",
                    "status": "RECRUITING",
                    "city": "Glendale",
                    "state": "California",
                    "zip": "91204",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Logi El-Harazi",
                            "role": "CONTACT",
                            "email": "logi@grmclinical.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.14251,
                        "lon": -118.25508
                    }
                },
                {
                    "facility": "Eye Research Foundation",
                    "status": "RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Linda Wirta",
                            "role": "CONTACT",
                            "email": "linda.wirta@drwirta.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}